Eluminex Biosciences Ltd. has presented results from preclinical studies of EB-105, a humanized trispecific antibody targeting IL-6 receptor (IL-6R), vascular endothelial growth factors (VEGFs) and angiopoietin-2 (Ang-2) for the treatment of diabetic macular edema.
“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that has gained the backing of an impressive group of investors in a recently closed $100 million series A round.
Eluminex Biosciences Ltd. announced the FDA’s acceptance of their IND application for EB-105, a trispecific fusion antibody targeting vascular endothelial growth factor A (VEGF-A, and isomers), VEGF-B, placental growth factor (PlGF), angiopoietin-2 (Ang-2) and interleukin-6 receptor (IL-6R) for the treatment of diabetic macular edema (DME).
Biolojic Design Ltd. announced that Nektar Therapeutics Inc. has exercised its license option to develop a program resulting from the companies’ 2021 research collaboration, established to design and test agonistic antibodies targeting tumor necrosis factor receptor type II (TNFR2).
Dysfunction of the complement system plays an important role in the pathogenesis of renal diseases. Complement inhibitors, such as C5 inhibitors, have shown efficacy in clinical trials, but may not be sufficient to block disease progression as monotherapy.
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., has received approval from the FDA and China’s National Medical Products Administration (NMPA) to conduct clinical trials with SIM-0500 in patients with relapsed or refractory multiple myeloma.
Tumors in the stomach and pancreas are known to express claudin 18.2 (CLDN18.2) and the absence of expression in normal tissues makes it an attractive therapeutic target.
T-cell-engaging antibodies (TCEs) are synthetic molecules that redirect T cells to bind to the antigens on the surface of cancer cells to promote tumor elimination. In the case of multiple myeloma (MM), the approvals of anti-CD38 monoclonal antibodies (MAbs), chimeric antigen receptor T-cell therapies (CAR T) targeting B-cell maturation antigen (BCMA) or, more recently, bispecific TCEs represent great advances, but some patients still relapse after treatment.
Preventing the interaction between the cellular adhesion integrin α4β7 and endothelial ligand mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) is a validated strategy for Crohn’s disease and ulcerative colitis treatment. Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical efficacy data on SPY-001, a long-acting monoclonal antibody targeting integrin α4β7.
RSS
